QTERN (SAXAGLIPTIN/DAPAGLIFLOZIN FDC) Regulatory Post-Marketing Surveillance

Clinical trial NCT05160974 · COMPLETED

Trial details

NCT number: NCT05160974
Sponsor: AstraZeneca
Status: COMPLETED
Study type: OBSERVATIONAL

Type 2 Diabetes Mellitus

Start date: 2021-12-30
Primary completion: 2024-04-01
Enrollment: 679

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.